We are excited to announce the proposed BCG-Unresponsive Trial – Combat HIVEC HEAT – in...
Announcing the HIVEC HEAT trial
read more
Our Blog
A history of hyperthermia therapy (part I)
In the first of three articles exploring the history of hyperthermia as a medical treatment,...
Short-term use of HIVEC in intermediate risk bladder-cancer patients is non-inferior to classical treatments and longer-term use shows great promise in Spanish trial
Press release, 1 December 2022 Combat Medical is pleased to announce the results of the HIVEC I...
“If we could kill the tumour without radical surgery, boy would that be a boon for patients. And I think that’s where we are headed”
The Medical Innovators Interview with Professor Brant Inman | July 2022 From superheated...
Growing data points towards use of HIVEC® in high-risk and BCG-unresponsive patients following publication of HIVEC® bladder cancer RCT results
Press release, 22 August 2022 Combat Medical is pleased to announce the results of the HIVEC® II...
“There’s a new vitality in bladder cancer. And it’s exciting to have come through 20 years of agony and start to see the fruits of all that labour”
The Medical Innovators Interview with Professor Michael O'Donnell | June 2022 Gem/doce vs BCG,...